Brief: Supernus Pharmaceuticals Inc Enters Into Settlement And License Agreements With Apotex Inc And Apotex Corp
23/06/2023 21:37
June 23 (Reuters) - Supernus Pharmaceuticals Inc
SUPN.O :
* SUPERNUS PHARMACEUTICALS INC - ON JUNE 21, ENTERED INTO
SETTLEMENT AND LICENSE AGREEMENTS WITH APOTEX INC. AND APOTEX
CORP
* SUPERNUS PHARMACEUTICALS: AGREEMENTS TO SETTLE ONGOING
PATENT
LITIGATION
* SUPERNUS PHARMACEUTICALS: GRANTS TO APOTEX A LICENSE TO
PATENTS-IN-SUIT TO MARKET GENERIC VERSION OF OXTELLAR XR(REG) IN
U.S. BEGINNING ON SEPT 1 2024
Source: (https://shorturl.at/drzA5)
Further company coverage: SUPN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Supernus Pharmaceuticals
See all newsHuron Consulting poised to hit fresh record ahead of S&P SmallCap addition
Brief: S&P Dow Jones Indices Msg Rangers And Huron Consulting Group Set To Join S&P Smallcap 600
Brief: Supernus Pharmaceuticals Says FDA Grants Seven Years Orphan-Drug Exclusivity For Onapgo
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE -Micron Technology, Ares Management, Boeing